Company news

AdAlta Ltd. news in 2023

AdAlta Ltd.'s news releases, calls and decks from 2023, newest first.

View company

New malaria inhibiting i-body

December 18, 2023

Chair address and CEO presentation to AGM

November 21, 2023

AD-214 Phase I extension clinical study - interim results

November 20, 2023

AdAlta closes oversubscribed $1.65 million raise

November 8, 2023

Oversubscribed placement result

November 6, 2023

Placement to raise up to $1.23million

November 2, 2023

AD-214 well tolerated in Phase I extension study

October 22, 2023

R&D tax refund received & R&D Loan repayment terms extended

October 17, 2023

Prof Foley invited presentation AD-214

September 25, 2023

Dosing simulations support AD-214 IV product profile

September 24, 2023

AD-214 Phase I extension study fully enrolled

September 19, 2023

AdAlta to Present at August 24th Virtual Investor Summit

August 16, 2023

AD-214 returns to clinic

August 3, 2023

$1.87 million raised in oversubscribed Shortfall facility

July 12, 2023

New AD-214 data de-risks clinical studies

July 6, 2023

AD-214 clinical trial approval

June 28, 2023

AdAlta to present at June 1 Virtual Investor Summit

May 30, 2023

AdAlta secures A$1.28 million in rights offer to advance AD-214

May 25, 2023

Rights Offer results

May 24, 2023

AdAlta to support early return to clinical trials of AD-214 with rights offer

May 1, 2023

Rights Offer to fund early return to clinic and growth

April 27, 2023

Publication highlights I-body potential in osteoporosis

January 24, 2023

AdAlta welcomes new substantial shareholders

January 23, 2023

Second Japan patent for AD-214

January 9, 2023

Decks in 2023